Literature DB >> 26038559

Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis.

Stacey N Harbour1, Craig L Maynard1, Carlene L Zindl1, Trenton R Schoeb2, Casey T Weaver3.   

Abstract

Th17 cells reactive to the enteric microbiota are central to the pathogenesis of certain types of inflammatory bowel disease. However, Th17 cells display substantial developmental plasticity, such that some progeny of Th17 cell precursors retain a predominantly IL-17A(+) phenotype, whereas others extinguish IL-17 expression and acquire expression of IFN-γ, giving rise to "Th1-like" cells. It remains unclear what role these subsets play in inflammatory bowel disease. Using a Th17 transfer model of colitis, we found that IFN-γ-deficient Th17 cells retained an IL-17A(+) phenotype and were unable to induce colitis in recipients. Development of disease required the transition of a subset of Th17 precursors to Th1-like cells and was contingent on the expression of both Stat4 and T-bet, but not the IL-12 or IFN-γ receptors. Moreover, Th17 cells could provide "help" for the development of pathogenic Th1 cells from naïve precursors. These results indicate that Th17 cells are potent mediators of colitis pathogenesis by dual mechanisms: by directly transitioning to Th1-like cells and by supporting the development of classic Th1 cells.

Entities:  

Keywords:  Th1; Th17; colitis

Mesh:

Substances:

Year:  2015        PMID: 26038559      PMCID: PMC4460486          DOI: 10.1073/pnas.1415675112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  48 in total

1.  Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages.

Authors:  Laurie E Harrington; Robin D Hatton; Paul R Mangan; Henrietta Turner; Theresa L Murphy; Kenneth M Murphy; Casey T Weaver
Journal:  Nat Immunol       Date:  2005-10-02       Impact factor: 25.606

2.  A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease.

Authors:  Robert Burakoff; Charles F Barish; Dennis Riff; Ronald Pruitt; William Y Chey; Francis A Farraye; Ira Shafran; Seymour Katz; Charles L Krone; Martha Vander Vliet; Christopher Stevens; Matthew L Sherman; Eric Jacobson; Ronald Bleday
Journal:  Inflamm Bowel Dis       Date:  2006-07       Impact factor: 5.325

3.  Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology.

Authors:  Holm H Uhlig; Brent S McKenzie; Sophie Hue; Claire Thompson; Barbara Joyce-Shaikh; Renata Stepankova; Nicolas Robinson; Sofia Buonocore; Helena Tlaskalova-Hogenova; Daniel J Cua; Fiona Powrie
Journal:  Immunity       Date:  2006-08       Impact factor: 31.745

4.  Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn's disease but not in ulcerative colitis.

Authors:  Carsten Schmidt; Thomas Giese; Bianca Ludwig; Ina Mueller-Molaian; Thomas Marth; Stefan Zeuzem; Stefan C Meuer; Andreas Stallmach
Journal:  Inflamm Bowel Dis       Date:  2005-01       Impact factor: 5.325

5.  IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6.

Authors:  David Yen; Jeanne Cheung; Heleen Scheerens; Frédérique Poulet; Terrill McClanahan; Brent McKenzie; Melanie A Kleinschek; Alex Owyang; Jeanine Mattson; Wendy Blumenschein; Erin Murphy; Manjiri Sathe; Daniel J Cua; Robert A Kastelein; Donna Rennick
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

6.  A distal conserved sequence element controls Ifng gene expression by T cells and NK cells.

Authors:  Robin D Hatton; Laurie E Harrington; Rita J Luther; Therese Wakefield; Karen M Janowski; James R Oliver; Roger L Lallone; Kenneth M Murphy; Casey T Weaver
Journal:  Immunity       Date:  2006-10-26       Impact factor: 31.745

7.  A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.

Authors:  W Reinisch; D W Hommes; G Van Assche; J-F Colombel; J-P Gendre; B Oldenburg; A Teml; K Geboes; H Ding; L Zhang; M Tang; M Cheng; S J H van Deventer; P Rutgeerts; T Pearce
Journal:  Gut       Date:  2006-02-21       Impact factor: 23.059

8.  Interleukin-23 drives innate and T cell-mediated intestinal inflammation.

Authors:  Sophie Hue; Philip Ahern; Sofia Buonocore; Marika C Kullberg; Daniel J Cua; Brent S McKenzie; Fiona Powrie; Kevin J Maloy
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

9.  IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.

Authors:  Marika C Kullberg; Dragana Jankovic; Carl G Feng; Sophie Hue; Peter L Gorelick; Brent S McKenzie; Daniel J Cua; Fiona Powrie; Allen W Cheever; Kevin J Maloy; Alan Sher
Journal:  J Exp Med       Date:  2006-10-09       Impact factor: 14.307

10.  Bacteria-triggered CD4(+) T regulatory cells suppress Helicobacter hepaticus-induced colitis.

Authors:  Marika C Kullberg; Dragana Jankovic; Peter L Gorelick; Patricia Caspar; John J Letterio; Allen W Cheever; Alan Sher
Journal:  J Exp Med       Date:  2002-08-19       Impact factor: 14.307

View more
  148 in total

Review 1.  Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

Authors:  Michel DuPage; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2016-02-15       Impact factor: 53.106

2.  IFN-γ-Expressing Th17 Cells Are Required for Development of Severe Ocular Surface Autoimmunity.

Authors:  Yihe Chen; Sunil K Chauhan; Chunyi Shao; Masahiro Omoto; Takenori Inomata; Reza Dana
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

3.  Innate Recognition of the Microbiota by TLR1 Promotes Epithelial Homeostasis and Prevents Chronic Inflammation.

Authors:  Karishma Kamdar; Andrew M F Johnson; Denise Chac; Kalisa Myers; Vrishika Kulur; Kyle Truevillian; R William DePaolo
Journal:  J Immunol       Date:  2018-05-23       Impact factor: 5.422

4.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

Review 5.  Impact of gut microbiota on gut-distal autoimmunity: a focus on T cells.

Authors:  Maran L Sprouse; Nicholas A Bates; Krysta M Felix; Hsin-Jung Joyce Wu
Journal:  Immunology       Date:  2019-01-21       Impact factor: 7.397

Review 6.  Helper T cell differentiation.

Authors:  Jordy Saravia; Nicole M Chapman; Hongbo Chi
Journal:  Cell Mol Immunol       Date:  2019-03-12       Impact factor: 11.530

7.  CD4+ Tissue-resident Memory T Cells Expand and Are a Major Source of Mucosal Tumour Necrosis Factor α in Active Crohn's Disease.

Authors:  Shrinivas Bishu; Mohammed El Zaatari; Atsushi Hayashi; Guoqing Hou; Nicole Bowers; Jami Kinnucan; Beth Manoogian; Michelle Muza-Moons; Min Zhang; Helmut Grasberger; Charlie Bourque; Weiping Zou; Peter D R Higgins; Jason R Spence; Ryan W Stidham; Nobuhiko Kamada; John Y Kao
Journal:  J Crohns Colitis       Date:  2019-07-25       Impact factor: 9.071

8.  M3 muscarinic acetylcholine receptor-reactive Th17 cells in primary Sjögren's syndrome.

Authors:  Saori Abe; Hiroto Tsuboi; Hanae Kudo; Hiromitsu Asashima; Yuko Ono; Fumika Honda; Hiroyuki Takahashi; Mizuki Yagishita; Shinya Hagiwara; Yuya Kondo; Isao Matsumoto; Takayuki Sumida
Journal:  JCI Insight       Date:  2020-08-06

Review 9.  The dichotomous nature of T helper 17 cells.

Authors:  Brigitta Stockinger; Sara Omenetti
Journal:  Nat Rev Immunol       Date:  2017-05-30       Impact factor: 53.106

10.  Elimination of CD4lowHLA-G+ T cells overcomes castration-resistance in prostate cancer therapy.

Authors:  Chao Wang; Jiahuan Chen; Qianfei Zhang; Wang Li; Shengbo Zhang; Yanjie Xu; Fang Wang; Bing Zhang; Yan Zhang; Wei-Qiang Gao
Journal:  Cell Res       Date:  2018-10-08       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.